SCHEMBL2366626

SCHEMBL2366626

CCOCC1COC(=O)N1c1ccc(C(=O)N2CCNCC2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.42
SIGMAR1 Q99720 1/20 0.41
ALDH1A1 P00352 3/20 0.40
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
GAA P10253 2/20 0.38
HSD17B3 P37058 1/20 0.38
KDM4E B2RXH2 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
HSD17B10 Q99714 1/20 0.37
CYP2D6 P10635 1/20 0.37
SLC6A2 P23975 1/20 0.37
SLC6A4 P31645 1/20 0.37
SLC6A3 Q01959 1/20 0.37
STAT1 P42224 1/20 0.37
MKNK1 Q9BUB5 1/20 0.36
MKNK2 Q9HBH9 1/20 0.36
GABRD O14764 1/20 0.36
GABRA1 P14867 1/20 0.36
GABRB1 P18505 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2366623 1.00 HPGD (0.42) HPGDSIGMAR1ALDH1A1KMT2AMEN1
SCHEMBL2365781 0.90 HPGD (0.43) HPGDSIGMAR1ALDH1A1KMT2AMEN1
SCHEMBL2365750 0.90 HPGD (0.43) HPGDSIGMAR1ALDH1A1KMT2AMEN1
SCHEMBL2366495 0.85 CPS1 (0.38) CYP2D6SLC6A2SLC6A4SLC6A3
SCHEMBL2366487 0.85 CPS1 (0.38) CYP2D6SLC6A2SLC6A4SLC6A3
SCHEMBL2366525 0.84 KMT2A (0.47) ALDH1A1KMT2AMEN1GAASTAT1
SCHEMBL2366528 0.84 KMT2A (0.47) ALDH1A1KMT2AMEN1GAASTAT1
SCHEMBL15015099 0.81 HPGD (0.48) HPGDSIGMAR1ALDH1A1GAAHSD17B3
SCHEMBL2365911 0.80 KMT2A (0.38) HPGDALDH1A1KMT2AMEN1GAA
SCHEMBL2365884 0.80 KMT2A (0.38) HPGDALDH1A1KMT2AMEN1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2364975-B1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORP (JP) 2013-06-12 EP disclosed
US-8354401-B2 Oxazolidinone amide aromatic compounds for supressing MMP-9 production MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-01-15 US disclosed
US-20110263571-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-10-27 US disclosed
EP-2364975-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2011-09-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263571-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP2 HPGD 135/4885SIGMAR1 4049/4885ALDH1A1 598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.